Download PDF
Semin Thromb Hemost 2019; 45(08): 837-845
DOI: 10.1055/s-0039-1695734
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Influence of Concomitant Treatments under Anticoagulants and Statins in Detecting Signals of Adverse Drug Reactions

Maria-Isabel Jimenez-Serrania
1   Departamento de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Europea Miguel de Cervantes, Valladolid, Spain
,
Carlos Treceño-Lobato
1   Departamento de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Europea Miguel de Cervantes, Valladolid, Spain
2   Consejo de Colegios Profesionales de Farmacéuticos de Castilla y León, Castilla y León, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
28 September 2019 (online)

    Permissions and Reprints

Abstract

The aim of the present study was to evaluate the risk of adverse drug reactions (ADRs) of concomitant treatments in patients treated with anticoagulants and statins. The authors performed an observational cross-sectional study in two cohorts of surveyed patients treated with vitamin K antagonists (VKAs) or non–vitamin K antagonist oral anticoagulants (NOACs). Different groups were analyzed based on the drug that each patient was taking, that is, VKAs or NOACs, as well as on the use of HMG CoA reductase inhibitors (statins) versus nonuse of these drugs; they also took into account the potential exposure to other common medications. Descriptive, clinical, and ADR data were reported and analyzed through an adaptation of Bayesian methodology (false discovery rate < 0.05) to detect new signals. Eleven different ADRs in patients on VKAs and statins and 12 in patients on VKAs without statins were found. In evaluating the concomitant therapies, the authors found that analgesics and nonsteroidal anti-inflammatory drugs were the most common therapeutic options, followed by proton pump inhibitors (PPIs). Seven ADRs were observed in patients concomitantly treated with NOACs and statins, whereas NOACs without concomitant statins were associated with a significantly lower risk of bleeding. The risk of observing an ADR among the patients who are concomitantly treated with VKAs and statins is lower than with analgesics or PPI, while the concomitant use of NOACs and statins is associated with both an increment in the number of observed ADRs and increased risk of bleeding.

Keywords

oral anticoagulant - vitamin K antagonist - bleeding - statins - interactions

Funding Support

The Sentinel Network in Castilla y León received funding support from Daiichi Sankyo España S.A.U. to assume the administrative cost of the project.


Supplementary Material

 

  • References

  • 1 Forbes HL, Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf 2017; 8 (10) 319-328
    CrossrefPubMedGoogle Scholar
  • 2 Damiani G, Federico B, Anselmi A. , et al. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Serv Res 2014; 14: 6
    CrossrefPubMedGoogle Scholar
  • 3 Chang SH, Chou IJ, Yeh YH. , et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318 (13) 1250-1259
    CrossrefPubMedGoogle Scholar
  • 4 Li Y, Dong S, Soria-Saucedo R. Drug interactions with non-vitamin K oral anticoagulants. JAMA 2018; 319 (08) 827-828
    CrossrefPubMedGoogle Scholar
  • 5 Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz 2015; 40 (Suppl. 02) 140-145
    CrossrefPubMedGoogle Scholar
  • 6 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (03) 455-466
    CrossrefPubMedGoogle Scholar
  • 7 Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol 2016; 82 (06) 1591-1600
    CrossrefPubMedGoogle Scholar
  • 8 Vakkalagadda B, Frost C, Byon W. , et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016; 16 (02) 119-127
    CrossrefPubMedGoogle Scholar
  • 9 Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9 (01) 59-68
    CrossrefPubMedGoogle Scholar
  • 10 Antoniou T, Macdonald EM, Yao Z. , et al; Canadian Drug Safety and Effectiveness Research Network. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ 2017; 189 (01) E4-E10
    CrossrefPubMedGoogle Scholar
  • 11 Bate A, Lindquist M, Edwards IR. , et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54 (04) 315-321
    CrossrefPubMedGoogle Scholar
  • 12 Treceño-Lobato C, Jiménez-Serranía MI, Martínez-García R, Corzo-Delibes F, Martín Arias LH. New anticoagulant agents: incidence of adverse drug reactions and new signals thereof. Semin Thromb Hemost 2019; 45 (02) 196-204
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información online de Medicamentos de la AEMPS-CIMA. Ministerio de Sanidad, Servicios Sociales e Igualdad. Sintrom® SPC [Internet] 2017 . Available at: https://www.aemps.gob.es/cima/dochtml/ft/58994/FichaTecnica_58994.html . Accessed August 15, 2017
    PubMed
  • 14 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información online de Medicamentos de la AEMPS-CIMA. Ministerio de Sanidad, Servicios Sociales e Igualdad. Xarelto® SPC [Internet] 2017 . Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000944/WC500057108.pdf . Accessed August 15, 2017
    PubMed
  • 15 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información online de Medicamentos de la AEMPS-CIMA. Ministerio de Sanidad, Servicios Sociales e Igualdad. Lixiana® SPC [Internet] 2017 . Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf . Accessed August 15, 2017
    PubMed
  • 16 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información online de Medicamentos de la AEMPS-CIMA. Ministerio de Sanidad, Servicios Sociales e Igualdad. Eliquis® SPC [Internet]. 2017 . Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf . Accessed August 15, 2017
    PubMed
  • 17 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información online de Medicamentos de la AEMPS-CIMA. Ministerio de Sanidad, Servicios Sociales e Igualdad. Pradaxa SPC [Internet]. 2017 . Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf . Accessed August 15, 2017
    PubMed
  • 18 Ahmed I, Haramburu F, Fourrier-Réglat A. , et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat Med 2009; 28 (13) 1774-1792
    CrossrefPubMedGoogle Scholar
  • 19 Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003; 12 (07) 559-574
    CrossrefPubMedGoogle Scholar
  • 20 Nóren N. . ed. A Monte Carlo Method for Bayesian Dependency Derivation. Gothenburg: Chalmers University of Technology; 2002
    Google Scholar
  • 21 Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24 (02) 285-290
    CrossrefPubMedGoogle Scholar
  • 22 Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996; 30 (12) 1399-1402
    CrossrefPubMedGoogle Scholar
  • 23 Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 2012; 21 (05) 485-493
    CrossrefPubMedGoogle Scholar
  • 24 Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008; 31 (07) 587-596
    CrossrefPubMedGoogle Scholar
  • 25 Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010; 11 (03) 323-332
    PubMedGoogle Scholar
  • 26 Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol 2014; 10 (01) 51-65
    CrossrefPubMedGoogle Scholar
  • 27 Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47 (07) 463-474
    CrossrefPubMedGoogle Scholar
  • 28 Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80 (06) 565-581
    PubMedGoogle Scholar
  • 29 Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007; 120 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 30 Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003; 23 (01) 109-112
    CrossrefPubMedGoogle Scholar
  • 31 Hughes GJ, Patel PN, Saxena N. Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy. Pharmacotherapy 2011; 31 (06) 591-597
    CrossrefPubMedGoogle Scholar
  • 32 Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol 2015; 71 (12) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 33 Verhoef TI, Zuurhout MJ, van Schie RM. , et al. The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. Br J Clin Pharmacol 2012; 74 (06) 1068-1069
    CrossrefPubMedGoogle Scholar
  • 34 Enderle C, Müller W, Grass U. Drug interaction: omeprazole and phenprocoumon. BMC Gastroenterol 2001; 1: 2
    CrossrefPubMedGoogle Scholar
  • 35 Chang M, Tybring G, Dahl M-L. , et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39 (05) 511-518
    CrossrefPubMedGoogle Scholar
  • 36 Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J 2014; 12: 26
    CrossrefPubMedGoogle Scholar
  • 37 Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev 2018; 7 (01) 55-61
    CrossrefPubMedGoogle Scholar